TG THERAPEUTICS, INC. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Michael S. Weiss (CEO) and Sean A. Power (CFO) certified the June 30, 2026 quarterly report on August 5, 2026, attesting that financial statements fairly present the company's condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud were disclosed.
Why this rating
Standard Sarbanes-Oxley Section 302/906 certification. Routine quarterly filing requirement; absence of disclosed deficiencies is mildly positive but expected.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.